Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis

Journal of Immunology

Volumn 163, Issue 12, 1999, Pages 6800-6809

  Manna, Sunil K ^a   Mukhopadhyay, Asok ^a   Van, Nguyen T ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SILYMARIN; STRESS ACTIVATED PROTEIN KINASE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; BINDING SITES; CERAMIDES; CHLORAMPHENICOL O-ACETYLTRANSFERASE; DNA; DNA-BINDING PROTEINS; ENZYME ACTIVATION; ENZYME REPRESSION; GENES, REPORTER; HELA CELLS; HUMANS; I-KAPPA B PROTEINS; IMMUNOSUPPRESSIVE AGENTS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JURKAT CELLS; LIPID PEROXIDATION; LIPOPOLYSACCHARIDES; MAP KINASE KINASE KINASE 1; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; OKADAIC ACID; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; SILYMARIN; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 0032715311     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Wattnberg, L.W. 1990. Inhibition of carcinogenesis by naturally occurring and synthetic compounds. In Antimutageneis and Anticarcinogenesis, Mechanism II. Y. Kuroda, D. M. Shankel, and M. D., eds. Plenum Press, New York, p. 155.
2. Valenzuela, A., and A. Garrido. 1994. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol. Res. 27:105.
3. Valenzuela, A., R. Guerra, and L. A. Videla. 1986. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med. 6:438.
4. Muzes, G., G. Deak, I. Lang, K. Nekam, P. Gergely, and J. Feher. 1991. Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Physiol. Hung. 78:3.
5. Dehmlow, C., N. Murawski, and H. de Groot. 1996. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci. 58:1591.
6. Valenzuela, A., M. Aspillaga, S. Vial, and R. Guerra. 1989. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med. 55:420.
7. Bosisio, E., C. Benelli, and O. Pirola. 1992. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharm. Res. 25:147.
8. Mereish, K. A., D. L. Bunner, D. R. Ragland, and D. A. Creasia. 1991. Protection against microcystin-LR-induced hepatotoxicity by silymarin: biochemistry, histopathology, and lethality. Pharm. Res. 8:273.
9. Carini, R., A. Comoglio, E. Albano, and G. Poli. 1992. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex ldB 1016. Biochem. Pharmacol. 43:2111.
10. Letteron, P., G. Labbe, C. Degott, A. Berson, B. Fromenty, M. Delaforge, D. Larrey, and D. Pessayre. 1990. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice: evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem. Pharmacol. 39: 2027.
11. Mourelle, M., P. Muriel, L. Favari, and T. Franco. 1989. Prevention of CCL4-induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol. 3:183.
12. Ferenci, P., B. Dragosics, H. Dittrich, H. Frank, L. Benda, H. Lochs, S. Meryn, W. Base, and B. Schneider. 1989. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol. 9:105.
13. Agarwal, R., S. K. Katiyar, D. W. Lundgren, and H. Mukhtar. 1994. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis 15:1099.
14. Katiyar, S. K., N. J. Korman, H. Mukhtar, and R. Agarwal. 1997. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J. Natl. Cancer Inst. 89:556.
15. Lahiri-Chatterjee, M., S. K. Katiyar, R. R. Mohan, and R. Agarwal. 1999. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 59:622.
16. Ahmad, N., H. Gali, S. Javed, and R. Agarwal. 1998. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem. Biophys. Res. Commun. 247:294.
17. 1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin. Cancer Res. 4:1055.
18. 1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res. 58:1920.
19. Zi, X., H. Mukhlar, and R. Agarwal. 1997. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem. Biophys. Res. Commun. 239:334.
20. De La Puerta, R., E. Martinez, L. Bravo, and M. C. Ahumada. 1996. Effect of silymarin on different acute inflammation models and on leukocyte migration. J. Pharm. Pharmacol. 48:968.
21. Baeuerle, P. A., and V. R. Baichwal. 1997. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules Adv. Immunol. 65:111.
22. Baichwal, V. R., and P. A. Baeuerle. 1997. Apoptosis: activate NF-κB or die? Curr. Biol. 7:R94.
23. Stancovski, I., and D. Baltimore. 1997. NF-κB activation: the IκB kinase revealed? Cell 91:299.
24. Zhou, G., and M. T. Kuo. 1997. NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol. Chem. 272:15174.
25. Chaturvedi, M. M., R. LaPushin, and B. B. Aggarwal. 1994. Tumor necrosis factor and lymphotoxin: qualitative and quantitative differences in the mediation of early and late cellular responses. J. Biol. Chem. 269:14575.
26. Chaturvedi, M. M., A. Kumar, B. G. Darnay, G. B. N. Chainy, S. Agarwal, and B. B. Aggarwal. 1997. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-κB activation, IκBα phosphorylation, and degradation. J. Biol. Chem. 272: 30129.
27. Kumar, A., and B. B. Aggarwal. 1999. Assay for redox sensitive kinases. Methods Enzymol. 300:339.
28. Haridas, V., B. G. Darnay, K. Natarajan, R. Heller, and B. B. Aggarwal. 1998. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, NF-κB activation, and c-Jun kinase activation. J. Immunol. 160:3152.
29. 2 in NF-κB activation by either cytokine in both primary and transformed endothelial cells. J. Biol. Chem. 272:25941.
30. Yamane, Y., M. Furuichi, R. Song, N. T. Van, R. T. Mulcahy, T. Ishikawa, and M. T. Kuo. 1998 Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. J. Biol. Chem. 273:31075.
31. Finco, T. S., A. A. Beg, and A. S. Baldwin. 1994. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. USA 91:11884.
32. Mahon T. M., and L. A. O'Neill. 1995. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-κB activation in T lymphocytes: evidence for covalent modification of the p50 subunit. J. Biol. Chem. 270:28557.
33. Whiteside, S. T., M. K. Ernst, O. LeBail, C. Laurent-Winter, N. R. Rice, and A. Israel. 1995. N- and C-terminal sequences control degradation of MAD3/IκBα in response to inducers of NF-κB activity. Mol. Cell. Biol. 15:5339.
34. Karin, M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270:16483.
35. Lee, F. S. J., J. Hagler, Z. J. Chen, and T. Maniatis. 1997. Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88:213.
36. Hirano, M., S. Osada, T. Aoki, S. Hirai, M. Hosaka, J Inoue, and S. Ohno. 1996. MEK kinase is involved in tumur necrosis factor alpha-induced NF-κB activation and degradation of IκB-α. J. Biol. Chem. 271:13234.
37. Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J.-I. Inoue, Z. Cao, and K. Matsumoto. 1999. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signaling pathway. Nature 398:252.
38. Cohen, L., W. J. Henzel, and P. A. Baeuerle. 1998. IKAP is a scaffold protein of the IκB kinase complex. Nature 395:292.
39. Zhao, Q., and F. S. Lee. 1999. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-κB through IκB kinase-α and IκB kinase-β. J. Biol. Chem. 274:8355.
40. Saliou, C., B. Rihn, J. Cillard, T. Okamoto, and L. Packer. 1998. Selective inhibition of NF-κB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett. 440:8.
41. Ueda, S., H. Nakamura, H. Masutani, T. Sasada, S. Yonehara, A. Takabayashi, Y. Yamaoka, and J. Yodoi. 1998. Redox regulation of caspase-3 (-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J. Immunol. 161:6689.
42. Buttke, T. M., and P. A. Sandstrom. 1994. Oxidative stress as a mediator of apoptosis. Immunol. Today 15:7.
43. Verheij, M., R. Bose, X. H. Lin, B. Yao, W. D. Jarvis, S. Grant, M. J. Birrer, E. Szabo, L. I. Zon, J. M. Kyriakis, et al. 1996. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75.
44. Guo, Y. L., K. Baysal, B. Kang, L. J. Yang, and J. R. Williamson. 1998. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-α in rat mesangial cells. J. Biol. Chem. 273:4027.
45. Roulston, A. C. Reinhard, P. Amiri, and L. T. Williams. 1998. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor α. J. Biol. Chem. 273:10232.
46. Cai, Z., M. Korner, N. Tarantino, and S. Chouaih. 1997. IκBα overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-κB activation but not tumor necrosis factor-α-induced apoptosis. J. Biol. Chem. 272:96.
47. Natoli, G., A. Costanzo, F. Guido, F. Moretti, A. Bernardo, V. L. Burgio, C. Agresti, and M. Levrero. 1998. Nuclear factor κB-independent cytoprotective pathways originating at tumor necrosis factor receptor-associated factor 2. J. Biol. Chem. 273:31262.
48. Bessho, R., K. Matsubara, M. Kubota, K. Kuwakado, H. Hirota, Y. Wakazono, Y. W. Lin, A. Okuda, M. Kawai, R. Nishikomori, et al. 1994. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor κB (NF-κB) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem. Pharmacol. 48:1883.
49. Abbadie, C., N. Kabrun, F. Bouali, J. Smardova, D. Stehelin, B. Vandenbunder, and P. J. Enrietto. 1993. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell 75:899.
50. Manna, S., H. J. Zhang, T. Yan, L. W. Oberley, and B. B. Aggarwal. 1998. Overexpression of Mn-superoxide dismutase suppresses TNF-induced apoptosis and activation of nuclear transcription factor-κB and activated protein-1. J. Biol. Chem. 273:13245.
51. Manna, S. K., M. T. Kuo, and B. B. Aggarwal. 1999. Overexpression of γ-glutamylcysteine synthetase abolishes tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-κB and activator protein-1 Oncogene 18:4371.
52. Shrivastava, A., and B. B. Aggarwal. 1999. Antioxidants differentially regulate activation of nuclear factor-κB (NF-κB), activator protein-1, c-jun N-terminal kinases (JNK), and apoptosis induced by tumor necrosis factor. Antioxid. Redox Signaling 1:181.
53. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-κB by sodium salicylate and aspirin. Science 265:956.
54. Hahn, G., H. D. Lehmann, M. Kurten, H. Uebel, and G. Vogel. 1968. On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum (L.). Gaertn. Arzneimittel-Forschung. 18:698.